At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 11, doi. 10.1002/cpdd.1495
- By:
- Publication type:
- Article
Works matching IS 2160-763X AND VI 14 AND IP 1 AND DT 2025
Results: 11
1
2
A Phase 1 Study to Evaluate the Pharmacokinetic Drug‐Drug Interaction Between Islatravir and Methadone in Participants on Stable Methadone Therapy.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 36, doi. 10.1002/cpdd.1492
- By:
- Publication type:
- Article
3
Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 18, doi. 10.1002/cpdd.1488
- By:
- Publication type:
- Article
4
The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 79, doi. 10.1002/cpdd.1487
- By:
- Publication type:
- Article
5
Scp776, A Novel IGF‐1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo‐Controlled Phase 1 Studies in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 65, doi. 10.1002/cpdd.1486
- By:
- Publication type:
- Article
6
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Neonatal Fc Receptor Inhibitor Rozanolixizumab: An Ethnic Sensitivity Study in Healthy Japanese, Chinese, and White Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 26, doi. 10.1002/cpdd.1484
- By:
- Publication type:
- Article
7
Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 5, doi. 10.1002/cpdd.1483
- By:
- Publication type:
- Article
8
Safety, Tolerability, and Pharmacokinetic Profile of the Low‐Impact Ampakine CX1739 in Young Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 50, doi. 10.1002/cpdd.1475
- By:
- Publication type:
- Article
9
Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 44, doi. 10.1002/cpdd.1468
- By:
- Publication type:
- Article
10
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 1, doi. 10.1002/cpdd.1278
- Publication type:
- Article
11
Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2025, v. 14, n. 1, p. 59, doi. 10.1002/cpdd.1471
- By:
- Publication type:
- Article